K. Mahajan

Trimetazidine in Heart Failure: From Metabolic Modulation to Clinical Outcomes—A Narrative Review

Heart Failure (HF) remains a leading cause of morbidity and mortality worldwide despite major advances in guideline-directed medical therapy. Metabolic remodeling with impaired myocardial energy utilization has emerged as an important therapeutic target in HF. Trimetazidine, a metabolic modulator that partially inhibit...

Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)

Despite strong recommendations from the European Society of Cardiology / European Atherosclerosis Society for low-density lipoprotein cholesterol (LDL-C) <55 mg/dL after acute coronary syndrome (ACS), real-world attainment remains suboptimal. Whether systematic early reassessment, combined with the predominant us...

Letter to the Editor: Vitamin D deficiency and post-transplant diabetes in kidney recipients - opportunity for risk stratification and intervention

Vitamin D deficiency is highly prevalent worldwide, including in South Asia, and may contribute to dysglycemia by affecting insulin secretion, insulin sensitivity, and inflammation. Observational studies in the general population link lower 25-hydroxyvitamin D concentrations to a higher risk of incident type 2 diabetes...

World Journal of Nephrology

Clinical trials have demonstrated the efficacy of finerenone, a highly selective, non-steroidal MRA, in reducing renal and CV outcomes in patients with long-standing T2DM.

Aromatase inhibitors, GnRH analogues and growth hormone for short stature with advanced bone age in adolescent boys: a Bayesian network meta-analysis.

INTRODUCTION Adolescent boys presenting late with short stature and advanced bone age (BA/CA >1) have guarded height outcomes. Whether aromatase inhibitors (AI) or GnRH analogues (GnRHa) combined with growth hormone (GH) improve height is unknown. We compared AI+GH, GnRHa+GH, AI alone, and GH alone in boys with reduced...

World Journal of Nephrology

Aldosterone Synthase Inhibitors: Emerging Therapeutic Strategies in Resistant Hypertension

Resistant hypertension (RH) is a high-risk phenotype associated with increased cardiovascular and renal morbidity despite multidrug therapy. Dysregulation of the renin–angiotensin–aldosterone system (RAAS), particularly excess aldosterone activity, plays a central role in the pathophysiology of RH. Although conventiona...

β-Blocker Discontinuation after Myocardial Infarction without Reduced Ejection Fraction in the Revascularization Era: A Design-Coherent Bayesian Review & Meta-Analysis

In contemporary revascularized patients with preserved or mildly reduced EF, β-blocker discontinuation was not associated with a credible increase in death or MACE, whether stopped in the stable phase or the acute-withdrawal phase; the prior harm likely reflects immortal-time bias and inclusion of non-revascularized pa...

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

A Clinical Prioritization and Personalization Framework centered on individualized risk-based intensification, comprehensive residual risk management, and optimization of treatment delivery is proposed to achieve sustainable, patient-centered cardiovascular protection.